Fremanezumab
Pain / Migraine PreventionAlso known as: Ajovy
Mechanism
An antibody treatment for migraine prevention that works by capturing and neutralizing CGRP — the pain-signaling molecule released during migraines. Unlike erenumab which blocks the receptor, fremanezumab grabs CGRP itself before it can trigger a migraine. Uniquely offers both monthly (225mg) and quarterly (675mg) dosing options.
Technical detail
Humanized IgG2Δa monoclonal antibody targeting CGRP ligand (both alpha-CGRP and beta-CGRP isoforms). Binds CGRP with high affinity (KD ~30 pM), sequestering it and preventing receptor activation. IgG2Δa framework selected for reduced effector function (no ADCC/CDC). Targets both alpha-CGRP (predominant in trigeminal system) and beta-CGRP (enteric nervous system). Phase 3 HALO trials: monthly 225mg reduced episodic migraine days by 3.7 (vs. 2.2 placebo); quarterly 675mg showed similar efficacy. For chronic migraine: 4.6 fewer headache days vs. 2.5 placebo. Half-life ~31 days. Unique quarterly dosing option (675mg = 3 x 225mg injections at one visit). Spring-loaded autoinjector for self-administration. No liver safety signals. Can be used with other preventive medications.
Effects
NERVOUS SYSTEM (MIGRAINE): Fremanezumab (Ajovy) is a fully humanized monoclonal antibody that selectively binds and neutralizes calcitonin gene-related peptide (CGRP) — targeting the ligand rather than the receptor (unlike erenumab). By sequestering free CGRP in the circulation and perivascular space, fremanezumab prevents CGRP from activating its receptor on trigeminal neurons, meningeal vasculature, and brainstem pain-processing nuclei [pharmacological]. MIGRAINE PREVENTION (EPISODIC): HALO-EM trial — monthly fremanezumab 225mg reduced monthly migraine days by -3.7 (vs. -2.2 placebo). Quarterly fremanezumab 675mg: -3.4 days (vs. -2.2 placebo). 50% responder rate: 47.7% (monthly), 44.4% (quarterly) vs. 27.9% placebo [RCT — Dodick et al., 2018, JAMA]. MIGRAINE PREVENTION (CHRONIC): HALO-CM trial — monthly dosing: -4.6 migraine days (vs. -2.5 placebo). Quarterly: -4.3 days (vs. -2.5 placebo). 50% responder rate: 41% (monthly), 38% (quarterly) vs. 18% placebo [RCT — Silberstein et al., 2017, NEJM]. UNIQUE DOSING FLEXIBILITY: Fremanezumab is the only CGRP antibody offering both monthly (225mg) and quarterly (675mg) dosing options. The quarterly regimen (3 injections of 225mg in a single session every 3 months) provides equivalent efficacy to monthly dosing — this is a significant adherence advantage for patients who dislike frequent injections or have difficulty maintaining monthly schedules [RCT]. CARDIOVASCULAR: Like all anti-CGRP therapies, theoretical concern about blocking a vasodilatory peptide. Clinical data shows no significant cardiovascular signal in trials or post-marketing. No blood pressure changes observed [RCT, post-market]. SIDE EFFECTS: Generally well-tolerated. Injection site reactions (redness, induration, pain) in 25-30% — higher than erenumab and galcanezumab, possibly due to formulation or injection volume. Constipation less commonly reported than with erenumab (consistent with ligand-targeting vs. receptor-blocking mechanism — ligand sequestration may allow some residual CGRP signaling at the receptor) [clinical observation, post-marketing comparison].
Practitioner Guide
ADMINISTRATION: Subcutaneous injection. Two dosing options: (1) Monthly: 225mg SC (single injection) once monthly. (2) Quarterly: 675mg SC (three consecutive 225mg injections in different sites) every 3 months. Both regimens are FDA-approved and show equivalent efficacy — patient preference drives selection. Injection sites: abdomen, thigh, upper arm. Allow prefilled syringe/autoinjector to reach room temperature for 30 minutes before injection (reduces pain). DOSING STRATEGY: Start with patient preference — some prefer the convenience of quarterly dosing (especially those with injection aversion or poor adherence to monthly schedules), others prefer the lower volume of monthly single injection. If starting quarterly: administer all 3 injections in one visit (different sites at least 1 inch apart). Reassess at 3 months (quarterly) or 3 months (monthly) — allow adequate time before switching approach. QUARTERLY DOSING — THE ADHERENCE ADVANTAGE: Medication adherence in migraine prevention is notoriously poor — studies show 50-70% of patients discontinue oral preventives within 6 months. The quarterly option reduces touchpoints from 12/year to 4/year. Particularly valuable for patients with: busy schedules, injection anxiety (get it over with once per quarter), cognitive issues making monthly scheduling difficult, or those traveling frequently. SWITCHING FROM OTHER CGRP THERAPIES: If a patient fails erenumab (receptor-targeted), switching to fremanezumab (ligand-targeted) is rational — different mechanism may capture different patient populations. Wait until the next scheduled dose of the previous therapy, then start fremanezumab. No washout period needed. FOCUS trial specifically studied fremanezumab in patients who had failed 2-4 prior preventive classes — demonstrated significant efficacy, confirming utility in treatment-resistant patients [Phase 3b]. COMBINATION: Safe to combine with triptans for acute treatment. Can add to oral preventives for refractory patients. Avoid combining with other anti-CGRP antibodies (no data, redundant mechanism). INJECTION SITE REACTIONS: Higher rate than competitors — counsel patients that redness and induration at injection site is common and self-resolving (24-48 hours). Ice pack before injection may reduce local reactions. Rotate injection sites. INSURANCE/ACCESS: Prior authorization required — document failure of 2+ oral preventives. Teva patient assistance programs available. Cost approximately $550-700/month. STORAGE: Refrigerate (2-8°C). Can store at room temperature for up to 24 hours before use (single use). Protect from light.
Research Summary
TIER 1: HALO-EM (Dodick et al., 2018 — JAMA): Phase 3 episodic migraine — monthly and quarterly fremanezumab significantly reduced monthly migraine days vs. placebo. HALO-CM (Silberstein et al., 2017 — NEJM): Phase 3 chronic migraine — both regimens significantly reduced monthly headache days. FOCUS (Ferrari et al., 2019 — Lancet): Phase 3b in patients who failed 2-4 prior preventive classes — fremanezumab effective in treatment-resistant population. FDA approved September 2018. Open-label extensions showing sustained efficacy over 12+ months without tolerance. TIER 2: Systematic reviews and meta-analyses of CGRP monoclonal antibodies confirming class-level efficacy. Network meta-analyses comparing monthly vs. quarterly dosing (equivalent efficacy). Post-marketing safety analyses. Adherence analyses showing better persistence with quarterly dosing vs. monthly. Reviews comparing ligand-targeting vs. receptor-targeting CGRP antibodies. TIER 3: Real-world effectiveness data from headache registries. Patient preference studies (monthly vs. quarterly). Case reports of switching within CGRP class. Health economic analyses comparing CGRP antibodies. KEY FINDINGS: Fremanezumab is an effective CGRP-targeting migraine preventive with a unique quarterly dosing option that differentiates it from competitors. Efficacy is consistent with the CGRP class (3-4 fewer migraine days per month in episodic, 4-5 fewer in chronic). The quarterly option is a genuine clinical advantage for adherence. Injection site reactions are more common than competitors but manageable. GAPS: Head-to-head trials vs. other CGRP antibodies are very limited. Predictors of quarterly vs. monthly dosing preference understudied. Long-term (>5 year) safety data accumulating. Biomarkers for treatment response not identified. Optimal duration of treatment unclear. ACTIVE TRIALS: Fremanezumab in post-traumatic headache, medication overuse headache. Real-world comparative effectiveness studies. Long-term extension studies. Adherence and persistence comparisons across CGRP antibodies.